Raymond James Financial Inc. Invests $3.45 Million in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Raymond James Financial Inc. purchased a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 92,904 shares of the company's stock, valued at approximately $3,450,000. Raymond James Financial Inc. owned about 0.19% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its stake in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after acquiring an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after purchasing an additional 439,281 shares during the period. Hotchkis & Wiley Capital Management LLC bought a new position in Amphastar Pharmaceuticals in the third quarter worth approximately $10,804,000. Portolan Capital Management LLC increased its holdings in Amphastar Pharmaceuticals by 201.1% during the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company's stock worth $15,906,000 after purchasing an additional 218,901 shares during the period. Finally, Weiss Asset Management LP bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $4,967,000. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock traded up $0.56 during midday trading on Monday, hitting $28.99. The company had a trading volume of 547,881 shares, compared to its average volume of 439,278. Amphastar Pharmaceuticals, Inc. has a 12-month low of $25.89 and a 12-month high of $53.96. The company has a fifty day simple moving average of $30.94 and a 200 day simple moving average of $39.77. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 9.66, a PEG ratio of 2.19 and a beta of 0.77.

Remove Ads

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 27.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.